Europe Cell Expansion Market

Europe Cell Expansion Market Size (2024 to 2029)

The size of the Europe Cell Expansion Market is valued at USD 4.11 billion in 2024. It is projected to be growing at a CAGR of 18.3% to touch USD 9.53 billion by 2029 during the forecast period.

Cellular expansion is the large-scale artificial manufacturing of daughter cells from a single cell to support clinical studies. The regenerative medicinal drug enables the body to shape new functional tissue to replace faulty or lost ones, allowing for inadequate healing procedures. Cell enlargement is currently broadly used to enhance transplantation and treat various diseases such as rheumatoid arthritis, diabetes, etc. The growing demand for regenerative drugs offering faster outcomes and cellular-based treatment plans with too affected person compatibility is anticipated to boost the cellular expansion market.

The outstanding factors contributing to the cell expansion market are the growing numeral of GMP-certified manufacturing facilities, increasing investment by the authority for research, developing pervasiveness of recurrent diseases, and increased cell-based products and therapy expenses 3D cellular growth method. The increasing occurrence of chronic medical conditions is expected to promote the European cell expansion market over the forecast duration.

The constraints faced by the expansion of the cell expansion market include a skilled workforce and high-tech instrumentation. Ethical issues regarding cell biology studies, a high value of cellular-based research, and strict recommendations are some of the factors that could hamper the market growth.

Impact of COVID-19 on European Cell Expansion Market:

Cell-based methods, primarily using mesenchymal stromal cells (MSCs), offer a promising approach for mitigating the COVID-19 infection's adverse effects. This therapy has been shown to reduce pro-inflammatory cytokines' composition and repair corrupted tissues in COVID-19 patients. According to the WHO ICTRP and the NIH ClinicalTrials.gov databases, 27 clinical studies of MSC-based cell therapy approaches have begun in China since the onset of the COVID-19 outbreak and a growing academic number industry trial abroad. Regenerative medicine & stem cell research is one of the principal applications of cell expansion. It is a significant indicator of market growth as stem cell-based therapies show considerable potential in the COVID-19 study. Additionally, various cell expansion products (such as cell culture media) and instruments (such as bioreactors) are currently used in COVID-19 research. Consequently, the outbreak of the COVID-19 pandemic has positively changed the cell expansion market.

This market research report on the Europe Cell Expansion Market has been segmented and sub-segmented into the following categories:

By Product: 

• Instruments
• Consumables
• Disposables

By Cell Type: 

• Human Cells
  • Human Differentiated Stem Cells
  • Human Stem Cells
    • embryonic stem cells
    • Adult Stem Cells
• Animal Stem Cells

By Application: 

• Regenerative Medicine
• Stem Cell Research
• Cancer
• Cell-Based Research

By End User: 

• Hospitals
• Biotech and Pharma Companies
• Academic and Research Institutes

By Country: 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, the European cell expansion market holds the second position in terms of percentage globally. Due to several untapped markets linked with the growing number of reoccurring illnesses, there may be market growth in the region. Growing personal quarter investments through key businesses to grow R&D to expand marketplace margins will enhance market growth within the European region.

Some of the prominent companies leading the Europe cell expansion market profiled in the report include Beckman Coulter, Inc. (U.S.), Becton, Dickinson, and Company (U.S.), Corning, Inc. (U.S.), GE Healthcare (U.K.), Lonza (Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Terumo BCT, Inc. (U.S.), and Thermo Fisher Scientific, Inc. (U.S.)

Recent Market Happenings:

• In 2020, Danaher acquired the Biopharma business from General Electric Company's Life Sciences division to form a new division called Cytiva and act as a standalone operating company within Danaher's Life Sciences division.
• In 2020, Applikon Biotechnology partnered with Sotelab to strengthen South America's advanced cultivation systems market.
• In 2019, Thermo Fisher Scientific invested around USD 24 million in its Inchinnan, Scotland site to expand global bio-production capabilities with additional large-volume liquid manufacturing capacity for cell culture media to meet growing customer demand.